Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuropathic Pain
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Crossover AssignmentMasking: Single (Participant)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Both males and females
Description
The study hypothesis is that inhibition of Pgp efflux transporters will increase the CNS bio-distribution of the 5-HT3R antagonist ondansetron. Specifically: Intravenous administration of ondansetron is expected to yield low CSF exposure. Co-administration of ondansetron with intravenous tariquidar,...
The study hypothesis is that inhibition of Pgp efflux transporters will increase the CNS bio-distribution of the 5-HT3R antagonist ondansetron. Specifically: Intravenous administration of ondansetron is expected to yield low CSF exposure. Co-administration of ondansetron with intravenous tariquidar, an inhibitor of Pgp efflux transporters, will result in increased CSF exposure of ondansetron.
Tracking Information
- NCT #
- NCT03809234
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Simon Haroutounian, PhD Washington University School of Medicine
Get Well Soon